Improving The Prevention And Clinical Management Of Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$236,146.00
Summary
Modern methods of analysis employ complex tools that are not always available or easily understood by doctors making decisions. The dosing of antibiotics is usually constant, even though known factors influence its effectiveness. Similarly, how effective vaccines are can be estimated from routinely available data. This project will develop tools and strategies to assist doctors and public health authorities make the best decisions by improving the analysis of existing data.
Assessing Vaccine Effectiveness Of Publicly Funded Vaccination Programs In Queensland
Funder
National Health and Medical Research Council
Funding Amount
$99,883.00
Summary
I will measure how well three vaccines on the national immunisation schedule prevent disease in Queensland. Pertussis (whooping cough), rotavirus, and varicella (chicken-pox) vaccines will be assessed using routinely collected health data, such as disease notifications and hospitalisations, and vaccination data. The findings of this research will contribute to evaluating the effectiveness of these publicly funded vaccination programs and will provide an evidence base for future decision-making.
RV3 Rotavirus Vaccine: Phase I And II Clinical Trials Of A Human Neonatal Rotavirus Vaccine For The Global Community
Funder
National Health and Medical Research Council
Funding Amount
$1,099,123.00
Summary
Rotavirus infection is the leading cause of gastroenteritis responsible for over 600,000 deaths each year in children less than 5 years. Although 2 commercial vaccines are now available in Australia, the high cost and concern about the risk of side effects are barriers to widespread vaccine introduction. The goal of this study is to develop an effective rotavirus vaccine, administered to newborns that is affordable for the global community, able to be introduced cheaply in developing countries w ....Rotavirus infection is the leading cause of gastroenteritis responsible for over 600,000 deaths each year in children less than 5 years. Although 2 commercial vaccines are now available in Australia, the high cost and concern about the risk of side effects are barriers to widespread vaccine introduction. The goal of this study is to develop an effective rotavirus vaccine, administered to newborns that is affordable for the global community, able to be introduced cheaply in developing countries where the burden of morbidity and mortality is greatest.Read moreRead less
A Case-control Study Of Rotavirus Vaccine Effectiveness Against Gastroenteritis Hospitalisation Of Children In The NT
Funder
National Health and Medical Research Council
Funding Amount
$465,859.00
Summary
Almost 1 out of 5 children in remote Aboriginal communities are hospitalised with diarrhoea caused by rotavirus. This study will evaluate the impact of rotavirus vaccination in preventing these hospitalisations. In addition to making sure that vaccination works and that those at highest risk are receiving the benefits, it will assess the indirect impact against other causes of diarrhoea providing, critical information relevant to the vaccine's broader introduction in developing country settings.
TEXTMEDS – TEXT Messages To Improve MEDication Adherence And Secondary Prevention
Funder
National Health and Medical Research Council
Funding Amount
$1,406,875.00
Summary
TEXTMEDS will evaluate a highly innovative strategy to improve cardiovascular disease secondary prevention using cheap and widely available mobile phone technology. TEXTMEDS is a randomised controlled trial of 1400 patients with acute coronary syndrome that will examine the effect of a semi-personalised secondary prevention support program sent via mobile phone text message on the proportion taking appropriate medications for the secondary prevention of cardiovascular disease and on cardiovascul ....TEXTMEDS will evaluate a highly innovative strategy to improve cardiovascular disease secondary prevention using cheap and widely available mobile phone technology. TEXTMEDS is a randomised controlled trial of 1400 patients with acute coronary syndrome that will examine the effect of a semi-personalised secondary prevention support program sent via mobile phone text message on the proportion taking appropriate medications for the secondary prevention of cardiovascular disease and on cardiovascular risk factors levels (e.g. cholesterol).Read moreRead less
Understanding The Unique Contribution Of Sedentary Behaviour To The Cardio Metabolic Health Of Women
Funder
National Health and Medical Research Council
Funding Amount
$83,149.00
Summary
The risk of heart disease for women increases significantly with the menopause. New evidence suggests that sedentary behaviour (too much sitting as distinct from too little exercise) is also related to heart disease risk. Ms Howard's PhD research will identify whether TV time and other prolonged sitting pose a particular risk for women during and after the menopause. Her studies will identify whether there is a need for women's health recommendations on reducing sitting time.
Accurate Prediction Of Individual Risk To Disease From Genome-wide Association Studies
Funder
National Health and Medical Research Council
Funding Amount
$269,371.00
Summary
Risk for many complex diseases (such as psychiatric disorders or heart disease) has a substantial genetic component, however few specific high risk variants have been identified. Evidence is mounting that there are likely to be hundreds of risk loci each individually conferring a very low increase in relative risk for disease. We aim to develop methods that utilise information from multiple genetic risk variants simultaneously to create a 'genomic profile' of risk.
A Longitudinal Investigation Of The Efficacy Of Pharmacological Smoking Cessation Aids In Real-life Settings
Funder
National Health and Medical Research Council
Funding Amount
$592,837.00
Summary
Currently around 3 million Australians, or 17% of people aged 14 years and over, smoke tobacco daily. These smokers are at major risk of developing coronary heart disease, stroke, peripheral vascular disease, and a variety of cancers, including lung, laryngeal, oral, kidney, bladder, breast, pancreas and colon cancers. At any one time almost half of Australian smokers intend to quit smoking or have already set a date to do so but few (around 10%) succeed on each attempt. Clinical trials of quitt ....Currently around 3 million Australians, or 17% of people aged 14 years and over, smoke tobacco daily. These smokers are at major risk of developing coronary heart disease, stroke, peripheral vascular disease, and a variety of cancers, including lung, laryngeal, oral, kidney, bladder, breast, pancreas and colon cancers. At any one time almost half of Australian smokers intend to quit smoking or have already set a date to do so but few (around 10%) succeed on each attempt. Clinical trials of quitting aids, such as nicotine patches, gum and Zyban, suggest that smokers are around twice as likely to quit if using these. However clinical trials are conducted in artificial environments and these quitting aids appear to have a far smaller impact on successful quitting rates in the 'real world'. Pharmaceutical quitting aids are heavily advertised by drug companies and widely used in Australia. Futhermore the Commonwealth Government has invested over $133 million dollars subsidising such aids to Australian smokers in the past four years. However it is not known to what extent these quitting aids have made a difference to Australian smoking rates. Sales volumes of pharmaceutical quitting aids appear not to have translated into expected increases in numbers of smokers successfully quitting, suggesting they are less effective than clinical trials suggest. The present study aims to investigate whether pharmaceutical quitting aids actually are less effective in the 'real world', and if so, why.Read moreRead less
Development Of Contemporary Surveillance And Control Methodologies For Dengue And Other Mosquito-borne Viral Diseases.
Funder
National Health and Medical Research Council
Funding Amount
$512,290.00
Summary
This research proposal will address the need for better surveillance and control methodologies for mosquito-borne viral diseases and their vectors, including dengue and its global mosquito vector, Ae. aegypti, and a range of other important arboviral diseases throughout Australia. Research will focus in three areas: surveillance and control of Ross River and Barmah Forest viruses; development of contemporary risk management frameworks for dengue; and innovative investigations of insect age to pr ....This research proposal will address the need for better surveillance and control methodologies for mosquito-borne viral diseases and their vectors, including dengue and its global mosquito vector, Ae. aegypti, and a range of other important arboviral diseases throughout Australia. Research will focus in three areas: surveillance and control of Ross River and Barmah Forest viruses; development of contemporary risk management frameworks for dengue; and innovative investigations of insect age to provide evidence based monitoring and novel approaches to arbovirus disease prevention.Read moreRead less
Retinal Microvascular Signs In Angina And Coronary Artery Disease: The Australian Heart Eye Study (AHES)
Funder
National Health and Medical Research Council
Funding Amount
$631,223.00
Summary
The Australian Heart Eye Study will determine whether vessel signs from the retina at the back of the eye are an independent marker of heart disease as assessed by a coronary angiogram. New imaging techniques permit a rapid assessment of these signs. This project could lead to the development of an innovative, non-invasive test that could be used to screen people for the risk of coronary heart disease, in addition to traditional risk factors like blood pressure, smoking, cholesterol and obesity.